L. Reichling

Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.

S. Riddle, L. Reichling, Steven M. Riddle, 2009, Biochemical and biophysical research communications.

Pharmacological Characterization of Purified Recombinant mTOR FRB-Kinase Domain Using Fluorescence-Based Assays

K. Vedvik, K. Vogel, M. Robers, 2008, Journal of biomolecular screening.

Detection of Allosteric Kinase Inhibitors by Displacement of Active Site Probes

C. Lebakken, S. Riddle, L. Reichling, 2012, Journal of biomolecular screening.

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1*

D. Sabatini, N. Gray, Qingsong Liu, 2009, Journal of Biological Chemistry.

Development and Applications of a Broad-Coverage, TR-FRET-Based Kinase Binding Assay Platform

U. Singh, Hildegard C. Eliason, K. Vogel, 2009, Journal of biomolecular screening.

Homogenous Fluorescent Assays for Characterizing Small-Molecule Activators of AMP-Activated Protein Kinase (AMPK)

K. Vogel, X. Qian, L. Reichling, 2008, Current chemical genomics.

Investigation of leucine‐rich repeat kinase 2

E. Brown, W. Stochaj, P. Reinhart, 2009, The FEBS journal.

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1*

D. Sabatini, N. Gray, Qingsong Liu, 2009, Journal of Biological Chemistry.

Enzymological properties and novel assays

E. Brown, W. Stochaj, P. Reinhart, 2009 .